Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.

doi:10.1007/s10875-022-01273-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.

Journal of clinical immunology - 1 Aug 2022

Lobo Pilar Blanco, Guisado-Hernández Paloma, Villaoslada Isabel, de Felipe Beatriz, Carreras Carmen, Rodriguez Hector, Carazo-Gallego Begoña, Méndez-Echevarria Ana, Lucena José Manuel, Aljaro Pilar Ortiz, Castro María José, Noguera-Uclés José Francisco, Milner Joshua D, McCann Katelyn, Zimmerman Ofer, Freeman Alexandra F, Lionakis Michail S, Holland Steven M, Neth Olaf, Olbrich Peter

Abstract excerpt

PURPOSE: STAT1 gain-of-function (GOF) and dominant-negative (DN) STAT3 syndromes share clinical manifestations including infectious and inflammatory manifestations. Targeted treatment with Janus-kinase (JAK) inhibitors shows promising results in treating STAT1 GOF-associated symptoms while management of DN STAT3 patients has been largely supportive. We here assessed the impact of ruxolitinib on the JAK-STAT1/3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukin-6

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Share to STAT1 Transcription Factor

Share to STAT3 Transcription Factor

Source

Open in PubMed

Identifiers

PMID: 35507130
DOI: 10.1007/s10875-022-01273-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.PMID 35507130Read ↗

Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant negative STAT3 mutationsSemantic proximity Read ↗

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.Semantic proximity Read ↗

The JAK/STAT conundrum with mutational heterogeneity, immune defects, and the emergence of targeted therapies.Semantic proximity Read ↗

JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional ConsequencesSemantic proximity Read ↗

STAT1 and STAT3 mutations: important lessons for clinical immunologistsSemantic proximity Read ↗

The Goldilocks Principle of JAKs and STATs: Gain-of function mutations, loss-of-function mutations, and their clinical consequencesSemantic proximity Read ↗

Signal transducer and activator of transcription gain-of-function primary immunodeficiency/immunodysregulation disordersSemantic proximity Read ↗

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic InterventionSemantic proximity Read ↗

Phenotypes of STAT3 gain-of-function variant related to disruptive regulation of CXCL8/STAT3, KIT/STAT3, and IL-2/CD25/Treg axes.Semantic proximity Read ↗

The ups and downs of STAT3 function: too much, too little and human immune dysregulation.Semantic proximity Read ↗

Unique and shared signaling pathways cooperate to regulate the differentiation of human CD4+ T cells into distinct effector subsets.Semantic proximity Read ↗

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.